227. Osler disease Clinical trials / Disease details
Clinical trials : 56 / Drugs : 72 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01752049 (ClinicalTrials.gov) | May 2013 | 14/12/2012 | Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept | Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept | Hereditary Hemorrhagic Telangiectasia | Drug: Topical timolol maleate;Drug: placebo saline drops | Unity Health Toronto | University of California, San Francisco;The Hospital for Sick Children;University of Toronto;Sunnybrook Health Sciences Centre;Ryerson University;National Institute of Neurological Disorders and Stroke (NINDS) | Completed | 18 Years | N/A | All | 5 | N/A | Canada |